EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Persistence of Retinal Fluid after Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration

Dominic Wei Ting Yap, Benjamin Kye Jyn Tan, Kelvin Teo Yi Chong, Tien Yin Wong, Chui Ming Gemmy Cheung

Ophthalmology Retina · 2025-07 · 9 (7) · 603-617

DOI: 10.1016/j.oret.2025.01.010 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Ophthalmology Retina, 2025-07. Verfasst von Dominic Wei Ting Yap und 4 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Wet Macular Degeneration, Subretinal Fluid, Visual Acuity. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SingHealth, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TOPIC: To evaluate the prognosis of retinal fluid resolution in neovascular age-related macular degeneration (nAMD) after initiating treatment in terms of the prevalence of eyes with retinal fluid, the proportion of eyes which never achieve a fluid-free retina throughout the course of treatment, and the relationship between retinal fluid and visual acuity outcome. CLINICAL RELEVANCE: Retinal fluid often persists or recurs after initiating treatment for nAMD. It is unclear what proportion never achieve fluid resolution throughout their treatment course. METHODS: MEDLINE, Embase, and Web of Science were searched till May 2024 for randomized control trials (including post hoc analyses) and prospective studies treating nAMD patients with intravitreal anti-VEGF injections (CRD42023437516). To investigate the prevalence of persistent fluid, a meta-analysis of proportions was conducted at key time points. To estimate the proportion of poor-responding patients, iterative algorithms were used to simulate individual patient data from time-to-fluid-resolution Kaplan-Meier curves. Cure fractions from Weibull nonmixture cure models were meta-analyzed. Finally, the weighted mean best-corrected visual acuity (BCVA) difference (WMD) between patients with and without any fluid, subretinal fluid (SRF), or intraretinal fluid (IRF) was calculated. RESULTS: Fifty articles were included across the meta-analyzed outcomes. The pooled prevalence of retinal fluid was 41.4% (95% confidence interval [CI], 35.0%-48.0%) at 1 year, and 47.4% (95% CI, 38.5%-56.5%) at 2 years. The pooled median time to first fluid resolution was 10.2 weeks (95% CI, 7.66-14.59 weeks). Cure modeling suggests that 17.6% (95% CI, 11.9%-25.3%) of patients may never achieve a fluid-free finding in the long run despite prolonged treatment. Eyes with SRF had significantly higher BCVA compared with eyes without SRF at 12 months (WMD, 2.39 letters; 95% CI, 0.27-4.52; P 60 months), eyes with SRF had significantly higher BCVA compared to eyes without SRF (WMD, 7.69 letters; 95% CI, 2.79-12.59; P < 0.05). CONCLUSION: Notwithstanding the heterogeneity in studies included, our analysis estimates that nearly half of all treated patients have persistent retinal fluid after initiating treatment and a substantial 18% of patients may never attain complete fluid resolution. We confirm that SRF is associated with better visual outcomes, whereas IRF is associated with worse visual outcomes. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsWet Macular DegenerationSubretinal FluidVisual AcuityRanibizumabHumansIntravitreal InjectionsVascular Endothelial Growth Factor ATomography, Optical Coherence

Stichwörter der Autor:innen

Anti-VEGFCure modelingFluid resolutionNeovascular age-related macular degenerationTime-to-fluid resolution

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumab

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Advanced Eye and Clinic Surgery, Singapore; Singapore Eye Research Institute, Singapore.
  • Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore; Tsinghua Medicine, Tsinghua Univers…
  • Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore. Electronic address: gemmy.cheung.c.…

Förderung

  • SingHealth
  • National Medical Research Council

Zitieren

APA

Yap, D. W. T., Tan, B. K. J., Chong, K. T. Y., Wong, T. Y., & Cheung, C. M. G. (2025). Persistence of Retinal Fluid after Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 9(7), 603-617. https://doi.org/10.1016/j.oret.2025.01.010

Vancouver

Yap DWT, Tan BKJ, Chong KTY, Wong TY, Cheung CMG. Persistence of Retinal Fluid after Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2025;9(7):603-617. doi:10.1016/j.oret.2025.01.010

BibTeX
@article{Yap2025,
  author = {Yap, Dominic Wei Ting and Tan, Benjamin Kye Jyn and Chong, Kelvin Teo Yi and Wong, Tien Yin and Cheung, Chui Ming Gemmy},
  title = {Persistence of Retinal Fluid after Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration},
  journal = {Ophthalmology Retina},
  year = {2025},
  volume = {9},
  number = {7},
  pages = {603--617},
  doi = {10.1016/j.oret.2025.01.010}
}
Kostenlos starten →